{
    "clinical_study": {
        "@rank": "168163", 
        "arm_group": [
            {
                "arm_group_label": "ACWY-TT group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects primed and boosted with the MenACWY-TT vaccine."
            }, 
            {
                "arm_group_label": "MenCCRM group", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects primed and boosted with the Meningitec vaccine."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the long-term antibody persistence as well as\n      safety of GSK Biologicals' MenACWY-TT vaccine versus Meningitec up to 6 years after booster\n      vaccination administered in healthy 5 year old children in the study MENACWY-TT-048 EXT: 039\n      Y2, 3, 4, 5 (NCT00955682), who were primed with the same vaccine in the study MENACWY-TT-039\n      (NCT00474266) at 12 through 23 months of age."
        }, 
        "brief_title": "Study to Evaluate the Persistence of Antibodies After GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Infections, Meningococcal", 
        "condition_browse": {
            "mesh_term": "Meningococcal Infections"
        }, 
        "detailed_description": {
            "textblock": "The subjects in this study will be allocated to the same groups as in study MENACWY-TT-048\n      EXT: 039 Y2, 3, 4, 5 (NCT00955682). No vaccine will be administered during this long-term\n      persistence study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All subjects must satisfy ALL the following criteria at study entry:\n\n          -  Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion\n             of the investigator, can and will comply with the requirements of the protocol.\n\n          -  A male or female who has received primary and booster vaccination with the MenACWY-TT\n             or Meningitec vaccines in studies MENACWY-TT-039 (109670) and MENACWY-TT-048 EXT: 039\n             Y2, 3, 4, 5 (112036), respectively.\n\n          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.\n\n          -  Healthy subjects as established by medical history and clinical examination before\n             entering into the study.\n\n        Exclusion Criteria:\n\n        The following criteria should be checked at the time of study entry. If ANY exclusion\n        criterion applies, the subject must not be included in the study:\n\n          -  Child in care.\n\n          -  History of meningococcal disease.\n\n          -  Administration of a meningococcal polysaccharide or a meningococcal polysaccharide\n             conjugate vaccine outside of studies MENACWY-TT-039 (109670) and MENACWY-TT-048 EXT:\n             039 Y2, 3, 4, 5 (112036).\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on\n             medical history and physical examination.\n\n          -  Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Years", 
            "minimum_age": "7 Years"
        }, 
        "enrollment": {
            "#text": "248", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01900899", 
            "org_study_id": "200088", 
            "secondary_id": "2012-005816-25"
        }, 
        "intervention": {
            "arm_group_label": [
                "ACWY-TT group", 
                "MenCCRM group"
            ], 
            "description": "At 2, 3, 4, 5, 6 years after booster vaccination.", 
            "intervention_name": "Blood Sampling", 
            "intervention_type": "Procedure"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Healthy", 
            "Immunogenicity", 
            "Children", 
            "Neisseria meningitidis", 
            "Long-term antibody persistence", 
            "Safety", 
            "Serogroups A, C, W-135, and Y"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Espoo", 
                        "country": "Finland", 
                        "zip": "02230"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland", 
                        "zip": "00930"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland", 
                        "zip": "00100"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jarvenpaa", 
                        "country": "Finland", 
                        "zip": "04400"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oulu", 
                        "country": "Finland", 
                        "zip": "90220"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pori", 
                        "country": "Finland", 
                        "zip": "28100"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seinajoki", 
                        "country": "Finland", 
                        "zip": "60100"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampere", 
                        "country": "Finland", 
                        "zip": "33100"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turku", 
                        "country": "Finland", 
                        "zip": "20520"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vantaa", 
                        "country": "Finland", 
                        "zip": "01300"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Finland: FIMEA (Finnish Medicines Agency)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "rSBA-MenA, rSBA- MenC, rSBA-MenW-135 and rSBA-MenY titres.", 
            "measure": "Persistence of antibodies with respect to components of the investigational vaccine in terms of antibody titres.", 
            "safety_issue": "No", 
            "time_frame": "2, 3, 4, 5, 6 years after booster vaccination."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01900899"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY,  hSBA-MenA, hSBA-MenC, hSBA-MenW-135, hSBA-MenY titres and GMTs.", 
                "measure": "Persistence of antibodies with respect to components of the investigational vaccine in terms of antibody titres.", 
                "safety_issue": "No", 
                "time_frame": "2, 3, 4, 5, 6 years after booster vaccination."
            }, 
            {
                "measure": "Serious adverse events (SAEs).", 
                "safety_issue": "No", 
                "time_frame": "From the subject's last visit in study MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (NCT00955682) up to each yearly visit in the current study (i.e. 2, 3, 4, 5 and 6 years post booster vaccination)."
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}